ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q2 2023. The put-call ratio across all filers is 0.63 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $19,665 | +36.0% | 210 | +29.6% | 0.00% | – |
Q2 2023 | $14,459 | -87.3% | 162 | -84.8% | 0.00% | – |
Q1 2023 | $113,975 | -22.7% | 1,063 | -12.0% | 0.00% | – |
Q4 2022 | $147,533 | +13.5% | 1,208 | -3.6% | 0.00% | – |
Q3 2022 | $130,000 | +44.4% | 1,253 | +29.2% | 0.00% | – |
Q2 2022 | $90,000 | +25.0% | 970 | +58.2% | 0.00% | – |
Q1 2022 | $72,000 | -28.7% | 613 | -18.8% | 0.00% | – |
Q4 2021 | $101,000 | -30.8% | 755 | -17.8% | 0.00% | – |
Q3 2021 | $146,000 | +47.5% | 919 | +22.0% | 0.00% | – |
Q2 2021 | $99,000 | -6.6% | 753 | -7.7% | 0.00% | – |
Q1 2021 | $106,000 | -4.5% | 816 | +23.1% | 0.00% | – |
Q4 2020 | $111,000 | +9.9% | 663 | +1.7% | 0.00% | – |
Q3 2020 | $101,000 | -31.8% | 652 | -35.0% | 0.00% | – |
Q2 2020 | $148,000 | +117.6% | 1,003 | +66.6% | 0.00% | – |
Q1 2020 | $68,000 | +28.3% | 602 | +56.4% | 0.00% | – |
Q4 2019 | $53,000 | +231.2% | 385 | +129.2% | 0.00% | – |
Q3 2019 | $16,000 | -5.9% | 168 | +14.3% | 0.00% | – |
Q2 2019 | $17,000 | +13.3% | 147 | +12.2% | 0.00% | – |
Q1 2019 | $15,000 | +200.0% | 131 | +72.4% | 0.00% | – |
Q4 2018 | $5,000 | 0.0% | 76 | 0.0% | 0.00% | – |
Q3 2018 | $5,000 | 0.0% | 76 | 0.0% | 0.00% | – |
Q2 2018 | $5,000 | 0.0% | 76 | 0.0% | 0.00% | – |
Q1 2018 | $5,000 | +66.7% | 76 | 0.0% | 0.00% | – |
Q4 2017 | $3,000 | 0.0% | 76 | 0.0% | 0.00% | – |
Q3 2017 | $3,000 | +50.0% | 76 | 0.0% | 0.00% | – |
Q2 2017 | $2,000 | 0.0% | 76 | 0.0% | 0.00% | – |
Q1 2017 | $2,000 | 0.0% | 76 | 0.0% | 0.00% | – |
Q4 2016 | $2,000 | – | 76 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |